Trends in Opioid and Gabapentinoid Utilization: A Time‐Series Analysis Across 72 Countries From 2012 to 2023
Pharmacoepidemiology and Drug Safety · 2025-05 · 34 (5)
DOI: 10.1002/pds.70149 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 28.04.2025. Verfasst von Yilei Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Analgesics, Opioid, Gabapentin, Drug Utilization, Practice Patterns, Physicians'. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: AHRQ HHS, Agency for Healthcare Research and Quality.
Abstract (Originalsprache)
Purpose
We compare trends in gabapentinoid and opioid utilization overall and by economic development category. We also sought to predict future trends and assess correlations in gabapentinoid and opioid utilization.
Methods
We conducted a repeated cross‐sectional analysis of retail prescriptions for 72 countries from Q1 2012 to Q3 2023. We measured standardized units/1000 population for gabapentinoid and opioid sales, stratified by development category, and used time‐series models to predict trends for the following 3 years. Granger causality tests examined predictive relationships between gabapentinoid and opioid sales.
Results
Global gabapentinoid annual sales rose by 114.5% from 2012 to 2022, with a higher increase in developing (180.9%) than developed economies (110.0%). In contrast, annual opioid sales declined globally by 25.4%, with a 27.9% decrease in developed and a 16.8% increase in developing economies. Assuming current trends persist over the following 3 years, gabapentinoid quarterly sales are forecasted to rise by 7.7% in developed and 18.6% in developing economies, while opioid quarterly sales are expected to decrease by 9.5% and increase by 15.1%, respectively. Granger causality tests indicated that gabapentinoids may predict opioid sales globally for the following year, but opioids did not predict gabapentinoid sales.
Conclusion
We evaluated the global trends in gabapentinoid and opioid sales, suggesting important differences in pain management practices across developed and developing economies. Our findings highlight the need to ensure the safe use of gabapentinoids and opioids while balancing proper pain management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Division of General Internal Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Leslie dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
- Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Yilei Liu
Förderung
- AHRQ HHS
- Agency for Healthcare Research and Quality
Zitieren
APA
Liu, Y., Rothenberger, S. D., Tadrous, M., Shuey, B., Chaudhry, S., & Suda, K. J. (2025). Trends in Opioid and Gabapentinoid Utilization: A Time‐Series Analysis Across 72 Countries From 2012 to 2023. Pharmacoepidemiology and Drug Safety, 34(5). https://doi.org/10.1002/pds.70149
Vancouver
Liu Y, Rothenberger SD, Tadrous M, Shuey B, Chaudhry S, Suda KJ. Trends in Opioid and Gabapentinoid Utilization: A Time‐Series Analysis Across 72 Countries From 2012 to 2023. Pharmacoepidemiology and Drug Safety. 2025;34(5). doi:10.1002/pds.70149
BibTeX
@article{Liu2025,
author = {Liu, Yilei and Rothenberger, Scott D and Tadrous, Mina and Shuey, Bryant and Chaudhry, Shanzeh and Suda, Katie J},
title = {Trends in Opioid and Gabapentinoid Utilization: A Time‐Series Analysis Across 72 Countries From 2012 to 2023},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2025},
volume = {34},
number = {5},
doi = {10.1002/pds.70149}
}
EUVIMED